抗肿瘤人源化抗体药物的研究进展  

Research status and development of humanized anti-tumor antibody drugs

作　　者：何远[1] 张娟[1] 李致科[1] 王旻[1] 

机构地区：[1]中国药科大学,天然药物活性物质与功能国家重点实验室,江苏南京210009

出　　处：《药学学报》2012年第10期1269-1274,共6页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(81072561)

摘　　要：随着单克隆抗体技术的发展,治疗性抗体药物逐渐占据全球市场,主要应用于肿瘤治疗、抗移植排斥、自身免疫性疾病的治疗等。抗体药物可根据人源化程度不同,分为鼠源抗体、嵌合抗体、人源化抗体和全人源抗体。本文着眼于目前治疗性抗体药物研究热点,聚焦于抗肿瘤人源化抗体药物,结合已上市热点抗肿瘤人源化抗体药物实例,从抗体人源化技术以及人源化抗体生产的角度来阐述目前研究状况。同时,立足于国内外抗肿瘤人源化抗体药物的现状,分析未来发展趋势。With the development of therapeutic monoclonal antibodies, the therapeutic antibodies have increasingly dominated the global pharmacy market in recent years, which are concentrated on the treatment of carcinoma, transplant rejection, auto-immune diseases etc. Meanwhile, the therapeutic antibodies could be categorized on the humanized proportion into several different types, such as murine-derived antibody, chimeric antibody, humanized antibody and human antibody. Herein, we focused both on antibody research hot spots and humanized anti-tumor antibody drugs. Moreover, in accordance with the classical examples of humanized anti-tumor antibody drugs approved by relevant authorities worldwide, we explained the research status and situation from both the humanized technologies and production of humanized antibodies. Additionally, it seemingly rational and reasonable to demonstrate the trend of further humanized anti-tumor antibody drugs in the prospect of the present situation either domestic or overseas.

关 键 词：抗肿瘤人源化抗体 人源化技术 动物细胞生产 抗体药物发展 

分 类 号：R963[医药卫生—微生物与生化药学]